Pharma and life sciences leadership in the Middle East is increasingly being defined not by the size of a balance sheet, but by the ability to spot a gap in patient care and build a credible pathway to close it. As the region positions itself as a serious destination for clinical trials, biomarker research and next generation therapeutics, the leaders shaping that future are, more often than not, physicians who chose to become entrepreneurs rather than executives who later discovered healthcare solutions.
That description fits Adedapo Adesokan, President and CEO of Famamedic Inc., almost exactly. Trained as a physician, formed as a pharmacologist, and now running a company that moves from over-the-counter products to first-in-class therapeutics, Adesokan has spent nearly two decades building toward a single idea: identify where patients are underserved, then build the product, device or medicine that closes that gap.
His inclusion among the Middle East’s 10 Most Visionary Leaders in Pharma and Life Sciences, 2026 reflects not just what Famamedic Inc. has already built, but where the company is heading next, with the UAE named as its first international base outside the US and UK.
A Dream in Kwara State
Adedapo’s story begins far from the boardroom originally from Oyo Ile, Oyo state, but born in Lagos; the financial capital of Nigeria. Growing up in Ilorin, Kwara State, Nigeria, he had at just 13 years old, a vivid dream of travelling the world, presenting medical innovations at conferences, developing new medicines and collaborating internationally. He shared it with his late father, Professor Ayoade Adesokan, whose advice became the blueprint he still follows start with Medicine to understand unmet clinical needs, then move into Pharmacology and Therapeutics to build solutions around them.
He studied Medicine at the University of Ilorin in Nigeria, then relocated to Scotland, where he earned a master’s in clinical pharmacology and a PhD in Therapeutics from the University of Glasgow, completing his doctoral research at the Strathclyde Institute of Pharmacy and Biomedical Sciences. He went on to train in Emergency Medicine at Sherwood Forest Hospitals NHS Foundation Trust in England, spending nine years on the front line of a public health system that would sharpen his sense of exactly where patient care was falling short.
The Idea That Became Famamedic Inc.
The company’s origin traces to a single conversation in 2010, when Adedapo received a one of the Top 10 Student/Trainee Award at the American College of Clinical Pharmacology conference in Baltimore. A mentor he met there gave him a piece of strategic advice he has never let go of develop innovations in the UK first, then bringing them to the US for completion and launch. That model became the operating logic behind Famamedic Inc., founded at the H-2 Helix NJ innovation hub in New Brunswick, New Jersey.
Famamedic Inc’s focus areas, menopause, ageing, dementia, flu support, chronic non-healing wounds and endometriosis among them, are a direct extension of what Adedapo saw during his NHS years. The company’s method is simple to state and hard to execute, but it starts with the patient’s problem and work its backwards to a practical solution.
Dapi’s Discovery Pyramid: How Famamedic Inc Builds Its Pipeline
Adedapo’s framework for sequencing Famamedic Inc’s pipeline is what he calls Dapi’s Discovery Pyramid, a structure that runs from accessible, near-term products at its base to complex medical devices and repurposed medicines at its peak. Sequencing was born of necessity. During his residency years, limited time and resources meant the top of the Pyramid had to wait, so he built the ground up.
At the base, five over the counter products are now ready for launch. Cov-Aid TM Immune Support was developed to support respiratory function during acute flu illness, with UK clinical observational studies recording 96.7% efficacy in helping patients resolve symptoms within 24 to 48 hours with no side effect. The MenoCare TM Anti-Aging Range combines a consumer beauty product, a microneedle application system and skin rejuvenating face masks, developed with AI- assisted optimization and designed to deliver a five-to-ten-year younger facial appearance, particularly for menopausal women. Lactobacillus-Complex Energy 234, named after Adedapo’s April 23rd birthday, is a probiotic based energy drink built to support people managing chronic fatigue linked to conditions including chronic fatigue syndrome, diabetes and endometriosis.
Further up the Pyramid sit Famamedic Inc’s more ambitious projects: an AI-AR four-device system aimed at healing chronic non-healing wounds and reducing amputation risk, particularly for patients with diabetes and spinal cord injuries, alongside next generation innovations targeting endometriosis and pregnancy related complications. On the therapeutics side, the company holds assets positioned as first -in- class and first- in-human treatments for Statin Associated Muscle Symptoms, with repurposed candidates earmarked for future development in malaria, melanoma and multiple sclerosis. The commercial logic threading it all together is deliberate: use the visibility and capacity built through OTC products to fund and support the advance of more complex, fully licensed therapies.
Why Interdisciplinary Work and AI Matters to Famamedic Inc
Adedapo describes interdisciplinary collaboration as essential to getting Famamedic Inc’s innovations to patients faster, and points to his clinical training as what allows him to connect therapeutics, medical devices, diagnostics and technology around a single problem. Artificial intelligence, in his view, is not optional. Tasks that once consumed enormous amounts of human time, including the analysis and organization of clinical research data, can now be accelerated dramatically with AI. Used responsibly, alongside augmented reality and genomic medicine, he believes it can make Famamedic Inc’s work on unmet clinical needs faster and more efficient.
What Building Famamedic Inc Has Cost, and Taught
Adedapo is direct about Famamedic Inc’s biggest obstacle: funding. The expertise and technology needed to develop innovative healthcare solutions exist, he says, but securing sufficient capital to carry inventions through development, trials, regulatory approval and scale-up remains a persistent hurdle, one that shapes nearly every strategic decision the company makes.
What keeps the pipeline moving is a kind of restlessness. While one invention nears completion, another is in conceptual development, preclinical study, human trials or awaiting regulatory approval, and ideas do not keep office hours, including nights when one has pulled him out of bed at 2 a.m. to sketch a medical device. He traces his approach to leadership back to his maternal grandmother, Ibironke, and his mother, Olufunke, who used to tell him it takes more than one tree to make a forest, a principle he now applies directly to how he builds Famamedic’ Inc s team: value your people, respect their expertise, listen to them, and build together.
Taking Famamedic Inc to the Middle East
The Middle East is central to where Adedapo is taking Famamedic Inc next. The company plans to establish a facility in the UAE in early 2027 to pioneer the development of novel continuous biomarker monitoring systems and will launch its flagship OTC products in Dubai this coming November. A partnership with Dubai based CRO CliniBridge will see a significant share of Famamedic Inc’s clinical trials conducted in the region, meaning the Middle East is involved early in the development of the company’s emerging therapies rather than joining once products are already established elsewhere.
Adedapo sees the region as more than a market. Continuous biomarker and hormone monitoring, microneedle-based delivery systems, and advances in genomic screening and therapeutics are, in his view, among the technologies most likely to define the next decade of healthcare, and he wants Famamedic Inc ‘s Middle East operations built around exactly those capabilities from the outset.
The Partnerships Behind the Pipeline
Adedapo’s approach to international collaboration was shaped by a piece of advice from his accountant in Glasgow, John Jackson, who once told him not to be greedy and to go to the negotiating table with something tangible for the person sitting across from him. That principle now underpins how Famamedic Inc works with outside researchers and specialists: fair sharing of intellectual property, and arriving prepared with ideas, technologies and designs that offer collaborators genuine value. It is, he says, one of the greatest strengths of the company’s innovation journey.
What Comes After the OTC Launch
Women’s health, earlier cancer detection and novel therapeutics sit high on Famamedic Inc’s list of future priorities, with technologies such as artificial intelligence, augmented reality and genomic medicine, including CRISPR based approaches, expanding what is achievable. Adedapo frames the opportunity as one of matching the right technology to the right therapeutic target, improving diagnosis, personalizing treatment and developing better solutions for conditions that continue to carry heavy global morbidity and mortality.
Famamedic Inc’s immediate ambition is to establish itself as a significant player in the OTC market in the US and internationally from 2027, before advancing its pipeline of medical devices and repurposed synthetic medicines through further development and licensing. The larger purpose behind all of it, Adedapo says, has not changed since the company’s founding: create solutions that improve quality of life and help reduce the morbidity and mortality associated with major unmet clinical needs, pursued one innovation at a time.
TPPE-VPAH-ADAPT: The Principle Behind the Company
Adedapo’s leadership approach, and by extension Famamedic Inc’s internal culture, is distilled into a framework he calls TPPE-VPAH-ADAPT, standing for Talent, Purpose, Persistence and Education, combined with Visibility, Positioning, Authority and Hard Work. Talent need’s purpose, he explains; purpose requires persistence; and education must never stop. Add visibility, strategic positioning, authority and hard work, and above all the ability to adapt when plans go wrong, and ambitions are given the best chance of becoming reality. The principle forms the basis of his forthcoming book, The Making of the Physician-Entrepreneur Serial Biotech Inventor: The TPPE-VPAH-ADAPT Principle, which he plans to bring to Middle Eastern readers with Arabic subtitling.
A Visionary Measured by Impact
Adedapo points to winning the Best Medical Initiative Award in the UK in 2025 as his most significant recognition to date, one that pushed him and his team to aim higher still. He is candid that recognition, and more importantly impact, rather than financial reward, is what drives him, with his greatest professional pride resting on knowing that a Famamedic Inc innovation has genuinely improved a patient’s quality of life.
His message to healthcare leaders, policymakers, investors and innovators shaping the sector across the Middle East and beyond is one of responsible progress: embracing the potential of AI across healthcare innovation while never compromising patient safety. Regulators, innovators, investors and healthcare leaders, he argues, need to work together to build frameworks that enable responsible AI integration while maintaining rigorous safety standards, so that patients living with unmet clinical needs can benefit from innovation as safely, and as quickly, as possible. It is a fitting closing note for a leader whose entire company, from its first OTC product to its coming Dubai launch, has been built around that same promise.
Related Blogs: https://arabworldleaders.com/category/articles/
